ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: MannKind Corporation (MNKD) Report Updated: Oct 27, 2014 | Print This Page

Get more stock ratings by Louis Navellier

MannKind Corporation (MNKD)

Rating: Hold Volatility: Aggressive
Total Grade: C Industry: Biotechnology
Competitors: UTHR, MNOV, CMRX, RNA

Stock Analysis

Rating: Monthly View

A
B
C
D
F
October November December January February March April May June July August September

Rating: Weekly View

This Week: C down no change
Last Week: C same no change
Two Weeks Ago: C up no change
service keys

MannKind Corporation© quotemedia

Company Profile

MannKind Corporation, a development stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for diabetes and cancer in the United States. Its lead product candidate, AFREZZA inhalation powder, an ultra rapid-acting insulin therapy that is in late-stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia. The company also develops MKC1106-MT, an investigational cancer immunotherapy product, which is in Phase II clinical trials; and MKC204, which is in preclinical development stage for the treatment of malignancies and inflammatory diseases. MannKind Corporation was founded in 1991 and is headquartered in Valencia, California.

Recent News: MannKind Corporation